Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy

Objective. We aimed to demonstrate safety and efficacy of intravenous (IV) low molecular weight iron dextran (LMWID) during treatment of anemic stage 3 and 4 chronic kidney disease (CKD) patients. Methods. Efficacy data was obtained by retrospective chart review of 150 consecutively enrolled patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yessayan, Lenar, Sandhu, Ankur, Besarab, Anatole, Yessayan, Alexy, Frinak, Stan, Zasuwa, Gerard, Yee, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614118/
https://www.ncbi.nlm.nih.gov/pubmed/23573422
http://dx.doi.org/10.1155/2013/703038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614118/
https://www.ncbi.nlm.nih.gov/pubmed/23573422
http://dx.doi.org/10.1155/2013/703038

Ejemplares similares